Mechanisms of resistance to chemoterapeutic and antiangiogenic drugs as novel targets for pancreatic cancer therapy

Starting date
January 1, 2011
Duration (months)
60
Departments
Medicine
Managers or local contacts
Melisi Davide
Keyword
pancreatic cancer, treatment resistance, angiogenesis

Sponsors:

A.I.R.C. Associazione Italiana per la Ricerca sul Cancro
Funds: assigned and managed by the department

Project participants

Publications
Title Authors Year
NF-ºB as a target for pancreatic cancer therapy. C. Carbone;D. Melisi 2012
Pancreatic Cancer: between bench and bedside. D. Melisi;A. Budillon 2012
Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. C. Carbone;T. Moccia;C. Zhu;G. Paradiso;A. Budillon;P. J. Chiao;J. L. Abbruzzese;D. Melisi 2011
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. Vaccaro V; Melisi D; Bria E; Cuppone F; Ciuffreda L; Pino MS; Gelibter A; Tortora G; Cognetti F; Milella M 2011
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. D. Melisi;Q. Xia;G. Paradiso;J. Ling;T. Moccia;C. Carbone;A. Budillon;J. L. Abbruzzese;P. J. Chiao 2011

Activities

Research facilities